A Phase 2 multi-center open-label basket trial of ABI-009 (nab-sirolimus) for adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Principal Investigator
Alexander I. Spira, MD, PhD, FACPLocations
Fairfax Office
Arlington Office
Gainesville Office
Learn More About This Trial
Other Relevant Trials
A PHASE 1B/2, OPEN-LABEL, SAFETY, TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02)
Principal Investigator
Alexander I. Spira, MD, PhD, FACPAn Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors